Natural History Study of MNGIE
← catalyst calendarSponsored by Entrada Therapeutics, Inc. (industry) · TRDA — their whole pipeline →.
Phase
—
Status
Suspended
Study type
Observational
Enrollment
60estimated
Sites
5
Countries
Turkey (Türkiye), United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Business Reason
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-08-06 | actual | When the study began enrolling |
| Primary completion | Feb 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2020-01-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2021-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mitochondrial Neurogastrointestinal Encephalomyopathy
Intervention
- Other: Non-interventional
Primary outcome
what the primary-completion date above is the date OFMNGIE Clinical Course
measured 5 years
Permalink · TRDA's whole pipeline · Catalyst calendar · Every registered study · What changed